EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection

Abstract

The analysis of safety data from spontaneous reporting systems has a proven value for the detection and analysis of the risks of medicines following their placement on the market and use in medical practice. EudraVigilance is the pharmacovigilance database to manage the collection and analysis of suspected adverse reactions to medicines authorised in the European Economic Area. EudraVigilance first operated in December 2001, with access to the database being governed by the EudraVigilance access policy. We performed a literature search including data up to December 2016 to demonstrate how the data from EudraVigilance has been used in scientific publications. We describe the results, including by type of publication, research topics and drugs involved. In 50% of the publications, the data are used to describe safety issues, in 44% to analyse methodologies used in pharmacovigilance activities and in 6% to support clinical perspectives. We also outline a description of the use of the database by the European Union regulatory network. Driven by the full implementation of the 2010 pharmacovigilance legislation, EudraVigilance has undergone further enhancements together with a major revision of its access policy, taking into account the use of the new individual case safety report standard developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and the International Organization for Standardization. The aim of the broadened access is to facilitate more effective safety monitoring of authorised medicines, to make more data available for research and to provide better access to information on suspected adverse reactions for healthcare professionals and patients. In November 2017, the new full functionalities of EudraVigilance were launched, including the extensive web access to data on suspected adverse drug reactions and the possibilities for academic research institutions to request a more extensive dataset for the purposes of health research. The main objective of this article is to describe the new access to the database together with the opportunities that this new access can bring for research. It is intended to promote an appropriate use of the data to support the safe and effective use of medicines.Electronic supplementary materialThe online version of this article (10.1007/s40264-018-0647-1) contains supplementary material, which is available to authorized users.

Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data

“…In order to avoid misclassification of events, we categorized signs and symptoms based on clinical expertise. Finally, since restricted data elements were provided from the spontaneous reporting systems database with an on-line access tool, additional information useful to well define the event and the outcome, such as severity of underlying illness, causality assessment, as well as ADR narrative or follow-up, were unavailable [36].…”

An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity

“…Thus, the EV provides a rich dataset with global representation. 10 The traditional approach to estimating counts of an ADR is to develop a case definition using the Medical Dictionary for Regulatory Activities (MedDRA). 11 MedDRA (version 21.1) has a preferred term for "Dihydropyrimidine dehydrogenase deficiency."…”

“…Of the cases submitted in a postauthorization setting, 64% were submitted from outside the EEA and 36% from EEA countries. Thus, the EV provides a rich dataset with global representation …”

Improving the Safety of Medicines in the European Union: From Signals to Action

“…EV is the EU system for managing and analyzing reports of suspected ADRs to medicines that are authorized or being studied in clinical trials . Monitoring of EV data is governed by EU law, and the schematic in Figure summaries the process demonstrating the six main activities (signal detection, signal validation, signal confirmation, signal analysis and prioritization, signal assessment, and recommendation) and the individual roles and interactions between the National Competent Authorities (NCAs), the European Medicines Agency (EMA), and MAHs…”